Cytokinetics (CYTK) said Monday it has dosed the first participants in a phase 1 clinical study of CK-4015089 as a potential treatment for a specific type of muscular dystrophy and other impaired muscle conditions.
The randomized, double-blind, placebo-controlled study consists of single-dose and multiple-dose ascending cohorts of 10 participants each, said the company
The drug, also called CK-089, increased muscle force and function in animal testing, the company said.
Shares of the company were up 2% in recent Monday premarket activity.
Price: 57.00, Change: +1.16, Percent Change: +2.08
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments